These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16255536)

  • 1. [New alternative drug therapy for reducing symptoms associated with the functional gastric disorders].
    Vasil'ev IuV; Masharova AA; Ianova OB
    Eksp Klin Gastroenterol; 2005; (4):39-41. PubMed ID: 16255536
    [No Abstract]   [Full Text] [Related]  

  • 2. [Functional disorders of the upper digestive system. Therapy].
    Moyrand H; Chevrel B; Morel R
    Med Chir Dig; 1978; 7(5):453-7. PubMed ID: 364205
    [No Abstract]   [Full Text] [Related]  

  • 3. [The influence of melatonin on concentration of nitric oxide metabolites in gastric juice in subjects with functional dyspepsia].
    Walecka-Kapica E; Klupińska G; Harasiuk A; Felicka E; Foryś S; Chojnacki C
    Pol Merkur Lekarski; 2007 May; 22(131):332-5. PubMed ID: 17679361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phytotherapy of functional stomach diseases].
    Stakhiv IV
    Farm Zh; 1980 Jun; (3):67-9. PubMed ID: 7409124
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic activity of betaine aspartate].
    Nicrosini F
    Clin Ter; 1972 May; 61(3):227-36. PubMed ID: 5050945
    [No Abstract]   [Full Text] [Related]  

  • 6. [Differences between European guideline and planned S3 guideline of DGVS. Need for Helicobacter pylori eradication to be decided on an individual basis].
    MMW Fortschr Med; 2008 Jun; 150(23):48-9. PubMed ID: 18578071
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new mode of using bismuth in gastroenterology. Report on experimentation in 49 cases].
    Poirier JP
    Therapeutique; 1970 Mar; 46(3):303-5. PubMed ID: 5422198
    [No Abstract]   [Full Text] [Related]  

  • 8. [Betaine aspartate in the hepato-digestive domain].
    Cachin M; Pergola F
    Sem Ther; 1966 Oct; 42(8):423-4. PubMed ID: 5994378
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictors of the placebo response in functional dyspepsia.
    Talley NJ; Locke GR; Lahr BD; Zinsmeister AR; Cohard-Radice M; D'Elia TV; Tack J; Earnest DL
    Aliment Pharmacol Ther; 2006 Apr; 23(7):923-36. PubMed ID: 16573795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia.
    Tack J; Van Den Elzen B; Tytgat G; Wajs E; Van Nueten L; De Ridder F; Boeckxstaens G
    Neurogastroenterol Motil; 2009 Jun; 21(6):619-26, e23-4. PubMed ID: 19220756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical tests of a new drug combination in the treatment of asthenia, anorexia and dyspeptic syndrome].
    Naufal JE
    Hospital (Rio J); 1968 Sep; 74(3):831-5. PubMed ID: 5310122
    [No Abstract]   [Full Text] [Related]  

  • 12. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia.
    Miner PB; Rodriguez-Stanley S; Proskin HM; Kianifard F; Bottoli I
    Curr Med Res Opin; 2008 Aug; 24(8):2159-72. PubMed ID: 18561877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors for dyspepsia.
    Vakil N
    Dig Dis; 2008; 26(3):215-7. PubMed ID: 18463438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model.
    Madsen LG; Bytzer P
    Dig Dis; 2008; 26(3):237-42. PubMed ID: 18463442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of gastric accommodation in the pathophysiology of functional dyspepsia.
    Di Stefano M; Miceli E; Mazzocchi S; Tana P; Corazza GR
    Eur Rev Med Pharmacol Sci; 2005; 9(5 Suppl 1):23-8. PubMed ID: 16457126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience of treatment of patients with gastropathy induced by non-steroid anti-inflammatory drugs].
    Vakhrushev IaM; Loshchakova OIu
    Eksp Klin Gastroenterol; 2007; (1):60-3, 71. PubMed ID: 17547116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a phyto-compound on delayed gastric emptying in functional dyspepsia: a randomized-controlled study.
    Metugriachuk Y; Marotta F; Kuroi O; Tsuchiya J; Goh KL; Minelli E; Kawakita S
    J Dig Dis; 2008 Nov; 9(4):204-7. PubMed ID: 18959591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in drug development for functional gastrointestinal disorders. Part I: functional dyspepsia.
    Andresen V; Camilleri M
    Neurogastroenterol Motil; 2006 May; 18(5):346-53. PubMed ID: 16629861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a muscarinic M3 receptor agonist on gastric motility.
    Chiba T; Kudara N; Sato M; Inomata M; Orii S; Suzuki K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2039-41. PubMed ID: 17914991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metoclopramide in the treatment of gastric functional disorders].
    Tkaczewski W; Gebicki L; Chojnacki J; Rynkiewicz K
    Wiad Lek; 1980 Oct; 33(19):1531-4. PubMed ID: 7467325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.